Biognosys
High-throughput workflows promise to boost discovery efforts, but some question whether they currently deliver the necessary depth of coverage.
Biognosys, Siemens Healthineers Partner for Protein Biomarker Development
The firms will use Biognosys' mass spectrometry technology to discover novel biomarkers, which they will then validate for potential clinical applications.
New mass spec offerings indicate the field is making progress in plasma proteome profiling, though some researchers remain skeptical of the projected gains.
The approach is able to look at structure and function across large numbers of proteins, adding data beyond traditional expression-based measurements.
Working with ETH Zurich researchers, the firm has incorporated machine learning to improve the platform's performance in complex organisms like humans.